Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study

BACKGROUND: Temsirolimus is an mTOR inhibitor with single-agent antitumor activity in patients with mantle cell lymphoma (MCL). We therefore tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with relapsed or refractory MCL. METHODS: Patients received temsirol...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Ansell, Stephen M., Tang, Hui, Kurtin, Paul J., Koenig, Patricia A., Inwards, David J., Shah, Keith, Ziesmer, Steven C., Feldman, Andrew L., Rao, Radha, Gupta, Mamta, Erlichman, Charles, Witzig, Thomas E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2011
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3106222/
https://ncbi.nlm.nih.gov/pubmed/21440503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70062-6
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन